# Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

> **NCT04167137** · PHASE1 · TERMINATED · sponsor: **Synlogic** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Solid Neoplasm
- Lymphoma

## Interventions

- **DRUG:** SYNB1891
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04167137
- **Lead sponsor:** Synlogic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-12
- **Primary completion:** 2021-12-09
- **Final completion:** 2021-12-09
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167137, "Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04167137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*